Current Developments and Events in Health

As Mutlu Medikim, we share the seminars, medical fairs, scientific conferences and all innovations in the field of health here, follow the developments.

ICECURE MEDICAL ANNOUNCES MONOPOLY DISTRIBUTION AGREEMENT FOR PROSENSE™ CRYOABLATION SYSTEM IN TURKEY

Caesarea, Israel – September 1, 2021 – IceCure Medical Ltd., NASDAQ: ICCM and TASE: ICCM, developer of next-generation minimally invasive cryoablation technology that destroys tumors by freezing them, announced that it has signed its first distribution agreement with Mutlu Medikim Tıbbi Malzemeleri Tic. A.Ş. for the sale of the ProSense™ Cryoablation System and probes in Turkey. A long-term exclusive distribution agreement is expected within twelve months of the agreement.

“This agreement opens a significant market opportunity for the ProSense™ Cryoablation System in Turkey. Turkey has a well-developed healthcare system supporting a population of over 80 million,” said Eyal Shamir, CEO of IceCure. “This first distribution agreement expands our regulatory and commercialization activities in the Middle East, Europe, Asia and Latin America.”

“We are excited to bring IceCure’s innovative cryoablation technology to Turkey,” said Cezmi Mutlu, Founder and President of Mutlu Medikim Inc. “As a well-established distributor of global medical products, we believe this system has great potential in the interventional oncology market.”

Under the initial distribution agreement, Mutlu Medikim Inc. will be responsible for all sales processes in Turkey and will place its first order for approximately $100,000.

 

ABOUT ICECURE MEDICAL
Founded in 2006, Israel-based IceCure Medical develops and markets advanced cryoablation systems that freeze tumors (benign and cancerous). Its primary targets are breast, kidney, bone and lung cancer. Its minimally invasive technology offers a safe and effective alternative to surgery in the hospital. The system, which has FDA and CE approvals, is marketed worldwide.

 

ABOUT MUTLU MEDİKİM A.Ş.
Based in Istanbul, Mutlu Medikim A.Ş. is part of a medical device distributor group that includes companies such as Opakim and MDS, and generated approximately $30 million in revenue in 2020. Founded in 1980, the company aims to be a major player in the Turkish market by focusing on interventional and IVD products.

 

FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Expressions such as “expects,” “anticipates,” “plans,” “believes” and similar expressions indicate future expectations. Actual results, performance and achievements may differ due to risk factors in the filings with the SEC at www.sec.gov.uk/index.php?topic=10 ...